Reeves Grafton D, Doyle Daniel A
Division of Endocrinology, Alfred I. duPont Hospital for Children, Wilmington, DE 19899, USA.
J Pediatr Endocrinol Metab. 2002 May;15 Suppl 2:723-30. doi: 10.1515/jpem.2002.15.s2.723.
Pseudotumor cerebri (PTC) is an uncommon disorder in the pediatric population. It is not a benign condition. It can cause permanent vision loss. The most recently recognized risk factor for this disorder is recombinant human growth hormone (GH) therapy. Data from Genentech's National Cooperative Growth Study (NCGS), a postmarketing surveillance program, are analyzed to examine the relationship between GH therapy and PTC. Several areas are addressed, including plausibility, probability, clinical and laboratory presentations, management, clinical outcome, present state of knowledge, and future recommendations.
假性脑瘤（PTC）在儿科人群中是一种罕见的疾病。它并非良性疾病。它可导致永久性视力丧失。这种疾病最近确认的风险因素是重组人生长激素（GH）治疗。对基因泰克公司的上市后监测项目国家合作生长研究（NCGS）的数据进行分析，以研究GH治疗与PTC之间的关系。探讨了几个方面，包括合理性、可能性、临床和实验室表现、管理、临床结果、现有知识状况以及未来建议。
